MIAMI LAKES, Fla., March 15, 2013 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce that they have added Kinney Drugs, a ninety store drug chain in the Northeastern United States, as a distribution partner for their line of proprietary and innovative consumer products, EnerJel, PowerFuse and ElectroFuse.
“We are very pleased with the new distribution relationship we have established with Kinney Drugs,” stated Brian Tuffin, CEO of Fuse Science, Inc. “We will begin shipping to Kinney Drugs in early April and look forward to having Fuse products available for consumers at check-out and at the pharmacy in this growing chain. Kinney Drugs is the next strategic partner in a series of planned distribution announcements in the coming days. We are focused on building a major national distribution presence and encouraged by retailer and consumer response to our proprietary technology,” added Tuffin.
EnerJelis Fuse Science’s innovative, performance-driven topical muscle and joint rub, which utilizes elements of their cutting edge delivery system. The proprietary formulation helps address site specific muscle fatigue, delivers an energized feeling and it is made with all-natural ingredients. PowerFuse and ElectroFuse are Fuse’s revolutionary consumable DROP products, which deliver “All The Energy You Need In A Single Drop” and “All The Electrolytes You Need In A Single Drop.”
About Kinney Drugs
Kinney Drugs is a chain of over 90 drug stores and pharmacies throughout Central and Northern New York, as well as Vermont. Its headquarters is located in Gouverneur, NY. For more information, visit: www.kinneydrugs.com.
About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated “DROP” form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).
For Fuse news as it happens, follow @Fuse_Science on Twitter and Like Us on Facebook HERE!
For more information: | To schedule an interview: |
Fuse Science, Inc. | Gus DeQuesada |
Investor Relations | Michelsen Advertising |
Direct: (305) 503-3873, Ext. 2 | C-305-733-1410 / 786-488-7138 |
Email: ir@fusescience.com |
Safe Harbor Statement
Certain statements and information included in this release may constitute “forward-looking statements” as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management’s projections, estimates and expectations is contained in the Company’s SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.
SOURCE Fuse Science, Inc.